Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties

Department of Endocrinology, Diabetes and Nutrition, Charite-Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany.

BACKGROUND: Glucocorticoids (GCs) are commonly used for long-term medication in immunosuppressive and anti-inflammatory therapy. However, the data describing gluco- and mineralo-corticoid (MC) properties of widely applied synthetic GCs are often based on diverse clinical observations and on a variety of in vitro tests under various conditions, which makes a quantitative comparison questionable. METHOD: We compared MC and GC properties of different steroids, often used in clinical practice, in the same in vitro test system (luciferase transactivation assay in CV-1 cells transfected with either hMR or hGRalpha expression vectors) complemented by a system to test the steroid binding affinities at the hMR (protein expression in T7-coupled rabbit reticulocyte lysate). RESULTS AND CONCLUSIONS: While the potency of a GC is increased by an 11-hydroxy group, both its potency and its selectivity are increased by the Delta1-dehydro-configuration and a hydrophobic residue in position 16 (16-methylene, 16alpha-methyl or 16beta-methyl group). Almost ideal GCs in terms of missing MC effects, as defined by our in vitro assay, are therefore prednylidene, budesonide, beclomethasone and betamethasone.The MC potency of a steroid is increased by a 9alpha- or a 6alpha-fluoro substituent. A hydrophilic substituent in position 16 (like 16-hydroxylation in triamcinolone) decreases both MC and GC properties. As no substituent that leads to an isolated reduction of GC activity could be characterized in our experiments, 9alpha-fluorocortisol, the most frequently used steroid for MC substitution, seems to be the best choice of available steroids for this purpose.

This article has been cited by other articles:

				H. C. Atkinson, S. A. Wood, E. S. Castrique, Y. M. Kershaw, C. C. R. Wiles, and S. L. Lightman Corticosteroids mediate fast feedback of the rat hypothalamic-pituitary-adrenal axis via the mineralocorticoid receptor Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1011 - E1022. [Abstract] [Full Text] [PDF]

				F. Spiga, L. R Harrison, S. A Wood, C. P MacSweeney, F. J Thomson, M. Craighead, M. Grassie, and S. L Lightman Effect of the glucocorticoid receptor antagonist Org 34850 on fast and delayed feedback of corticosterone release J. Endocrinol., February 1, 2008; 196(2): 323 - 330. [Abstract] [Full Text] [PDF]

				K.-B. Linhart and J. A. Majzoub Pomc Knockout Mice Have Secondary Hyperaldosteronism Despite an Absence of Adrenocorticotropin Endocrinology, February 1, 2008; 149(2): 681 - 686. [Abstract] [Full Text] [PDF]

				M. Salter, K. Biggadike, J. L. Matthews, M. R. West, M. V. Haase, S. N. Farrow, I. J. Uings, and D. W. Gray Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L660 - L667. [Abstract] [Full Text] [PDF]

				H. C. Thiesson, B. L. Jensen, C. Bistrup, P. D. Ottosen, A. D. McNeilly, R. Andrew, J. Seckl, and O. Skott Renal sodium retention in cirrhotic rats depends on glucocorticoid-mediated activation of mineralocorticoid receptor due to decreased renal 11beta-HSD-2 activity Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R625 - R636. [Abstract] [Full Text] [PDF]

				M Mandl, N Ghaffari-Tabrizi, J Haas, G Nohammer, and G Desoye Differential glucocorticoid effects on proliferation and invasion of human trophoblast cell lines Reproduction, July 1, 2006; 132(1): 159 - 167. [Abstract] [Full Text] [PDF]